Episode # 71 • 07 Jul 2026
Exploring PARP Inhibitor Combinations in Prostate Cancer
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient selection, timing, toxicity, and genetic testing are shaping the use of PARP inhibitor combinations in clinical practice.
This podcast is supported by an educational grant from Pfizer.
Timestamps
00:00 - Introduction
02:51 - PARPi Basics
14:12 - Major Study Differences
19:00 - Timing and Selection of PARPi Combinations
26:39 - Case: Somatic BRCA2 loss and mHSPC
35:51 - Case Continued: BRCA2 Reversion
39:57 - BRCAAway Study
42:59 - Takeaways from the 2026 APCCC
Resources
You may also like
More about this episode
The conversation reviews lessons learned from major clinical trials, including PROpel, MAGNITUDE, TALAPRO-2, and AMPLITUDE, and addresses how these studies inform real-world treatment choices. The doctors dig into case examples, such as BRCA2 loss and reversion, and highlight practical strategies for using germline and somatic testing to personalize care. Key insights from the 2026 Advanced Prostate Cancer Consensus Conference are also shared, emphasizing the importance of precision medicine in this rapidly evolving field.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.